- cafead Jul 19, 2023 at 10:53: AM
via Although these two anti-Aβ mAbs appear similar at first glance, there are several key differences that will likely set them apart.
article source
article source
-
Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page
Lilly’s donanemab flaunts strong clinical profile, ready to compete with Leqembi
- Thread starter cafead
- Start date
<
Similar threads